Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyoxalase 1 (GLO1) is a ubiquitous enzyme crucial for detoxifying methylglyoxal (MG), a cytotoxic byproduct of glycolysis. GLO1 catalyzes the conversion of MG, after it reacts with glutathione, into S-D-lactoylglutathione, which is further processed. It's a therapeutic target in cancer (inhibition) and potentially in conditions involving oxidative stress/AGE accumulation (activation).
GLO1 catalyzes the conversion of methylglyoxal-glutathione hemithioacetal to S-D-lactoylglutathione. Inhibitors block this enzymatic activity. Activators increase GLO1 expression or activity.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyoxalase 1 (GLO1).